Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Rutgers Health researchers found that prescription rates for preexposure prophylaxis rose overall, but racial disparities ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...

The agency approved Gilead Sciences' Stribild as a once-a-day treatment to control HIV in adults who have not previously been treated. The pill contains two previously approved antiviral drugs, ...

The agency approved Gilead Sciences' pill, Truvada, as a preventive measure for people who are at high risk of acquiring HIV through sexual activity, such as those who have HIV-infected partners.

The Sindh Healthcare Commission (SHCC) has taken immediate action following the emergence of HIV cases at Kulsoom Bai Valika Hospital in Karachi's Keamari district. Director Anti-Quackery Dr Zubair ...

One new HIV diagnosis was recorded in Hart last year, new figures show – as cases fell across England. It comes as the NHS announced the roll out of a new long-acting injection for people who are ...

The cost of HIV preexposure prophylaxis (PrEP) medication and care is a key barrier to PrEP use. Using population-based surveys and published information, we estimated the number of people with ...